Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial
Li W, Onishi N, Newitt D, Gibbs J, Wilmes L, Jones E, Joe B, Sit L, Yau C, Chien A, Price E, Albain K, Kuritza T, Morley K, Boughey J, Brandt K, Choudhery S, Clark A, Rosen M, McDonald E, Elias A, Wolverton D, Fountain K, Euhus D, Han H, Niell B, Drukteinis J, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Asare S, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Berry D, DeMichele A, Abe H, Sheth D, Edmiston K, Ellis E, Ha R, Wynn R, Crane E, Dillis C, Nelson M, Church A, Isaacs C, Khan Q, Oh K, Jafarian N, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Sheth P, Hovanessian-Larsen L, Eghtedari M, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Goudreau S, Brown T, Esserman L, Hylton N. Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial. Cancer Research 2020, 80: pd9-04-pd9-04. DOI: 10.1158/1538-7445.sabcs19-pd9-04.Peer-Reviewed Original ResearchI-SPY 2 TRIALFunctional tumor volumeTumor volume progressionTumor progressionNon-pCRI-SPYTumor volumeHER2 subtypeVolume progressionCancer subtypesTumour progressorsEvaluate MRI changesI-SPY 2Triple negative subtypeHER2+ tumorsHigh-risk patientsNegative predictive valueBreast cancer subtypesEnhancement post-contrastTime pointsNumbers of patientsInsufficient image qualityTreatment time pointsPost-NACPre-NACAbstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
Onishi N, Li W, Newitt D, Harnish R, Gibbs J, Jones E, Nguyen A, Wilmes L, Joe B, Campbell M, Basu A, van’t Veer L, DiMichele A, Yee D, Berry D, Albain K, Boughey J, Chien A, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, Asare S, Yau J, Yau C, Esserman L, Hylton N. Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer. Cancer Research 2020, 80: pd9-05-pd9-05. DOI: 10.1158/1538-7445.sabcs19-pd9-05.Peer-Reviewed Original ResearchPathological complete responseBackground parenchymal enhancementInferior treatment responseHormone receptor-positive breast cancerPathologic complete response rateReceptor-positive breast cancerPositive breast cancerTreatment responseHR cohortBreast cancerBreast MRINeoadjuvant chemotherapyNon-pCRDegree of BPEI-SPY 2 TRIALQuantitative background parenchymal enhancementStage II/III breast cancerContralateral breast parenchymaPost-NAC MRIHormone receptor statusHR+ breast cancerEffects of chemotherapyEnhanced suppressionStatistically significant associationHR+ cancers